- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Assessing Different Factors When Selecting a Treatment
Panelists discuss how comorbidities such as scoliosis, dislocated hips, and nutritional issues affect spinal muscular atrophy (SMA) treatment decisions, with treatment approaches evolving as patients' functional abilities improve with disease-modifying therapies.
EP: 1.Describing SMA Progression Over Time
EP: 2.Unmet Needs of Older Patients Living With SMA
EP: 3.Examining the Importance of Early Treatment for SMA
EP: 4.Key Functional Milestones Affected by Disease Progression
EP: 5.The Importance of Supportive Care for Patients Living With SMA
EP: 6.Introduction to Therapies Used to Treat SMA
EP: 7.Splicing Modifiers and Gene Therapy for SMA
EP: 8.Key Clinical Considerations for the Management of SMA
EP: 9.Assessing Different Factors When Selecting a Treatment
EP: 10.Evaluating the Potential of Intrathecal Gene Therapy
EP: 11.Other Investigational Treatment Options for SMA
EP: 12.Insurance Considerations for SMA Therapies
EP: 13.Optimizing Multidisciplinary Care Approaches for the Future of SMA Management
EP: 14.Final Panel Thoughts on the Management of SMA
Clinical Brief: Comorbidities and Changing Phenotypes in Patients With Treated SMA
Main Discussion Topics
- Impact of comorbidities on treatment decisions and management
- Challenges in addressing orthopedic issues in functionally improving patients
- Evolving patterns of scoliosis and spinal deformities in treated patients
- Reproductive considerations for patients with SMA
Key Points for Physicians
- Treatment has changed the natural history of SMA, creating new clinical challenges in managing comorbidities.
- Orthopedic interventions (for dislocated hips, scoliosis) require reassessment as patients gain function.
- Kyphosis is becoming more prominent than typical scoliosis in treated patients.
- Genetic counseling remains essential as disease-modifying therapies do not alter genetic status.
Notable Insights
The panel noted that disease-modifying treatments are not curative and do not change genetic inheritance patterns, necessitating continued genetic counseling for family planning.
Clinical Significance
As disease-modifying therapies alter the natural history of SMA, physicians must reconsider traditional approaches to comorbidities and develop new management paradigms for this evolving clinical landscape.
